Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0QPXBD
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
40285886 7300-LP3004
|
|||||
| Synonyms |
7300-LP3004
Click to Show/Hide
|
|||||
| Organization |
Donghua University.; Shanghai Tekanbio Pharm-Tech Co., Ltd.; East China Normal University.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Structure |
|
|||||
| Antibody Name |
7300
|
Antibody Info | ||||
| Antigen Name |
CD276 antigen (CD276)
|
Antigen Info | ||||
| Payload Name |
Camptothecin derivative 095
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase I (TOP1)
|
Target Info | ||||
| Linker Name |
a PSar-modified branched-link agent
|
Linker Info | ||||
ADC-specific functional property(2027 Update)
Bystander Killing Effect
| Bystander Killing Effect | Description | Reference |
|---|---|---|
| yes |
Bystander killing experiments were performed in vitro using Tras-LP3004 and lgG1-LP3004 (Tras-LP3004 refers to the ADC formed through the conjugation of trastuzumab and LP3004, while lgG1, an immunoglobulin, is not HER2-targeting). Raji-Luc cells were cultured alone or co-cultured with NCl-N87 cells (1:1 ratio of NCl-N87 to Raji-Luc). When only Raji-Luc cells were present, the two ADCs had no significant effect on the HER2-positive Raji-Luc cells (Figure 7a). However, it is noteworthy that Tras-LP3004 effectively inhibited Raji-Luc when they were cultured with NCl-N87 cells (Figure 7b). These findings suggest that Tras-LP3004 can indirectly kill Raji-Luc cells via the effect of HER2-positive NCl-N87 cells.
Click to Show/Hide
|
[1]
|
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
186.6 nM
|
|||
| Method Description |
SHP-77 cells were grown in RPMI-1640 medium supplemented with 10% FBS and 1 ug/mL puromycin at 37 °C in a 5% CO2 incubator. SHP-77 cells were dissociated using TrypLETM Express Enzyme (Thermo Fisher Scientific, Waltham, MA, USA) and, after counting, the cells were resuspended in RPMI-1640 medium supplemented with 10% FBS at a density of 3 × 104 cells/mL. The cells were plated in 96-well plates and incubated at 37 °C for 24 h. ADCs and payloads were diluted separately and added to the 96-well cell culture plates containing cells, followed by incubation in a 5% CO2 incubator for 5 days. A multifunctional microplate reader was used, and the absorbance was measured at 450 nm with a reference wavelength of 630 nm. The IC50 values were calculated using GraphPad Prism 10.1.2 software.
Click to Show/Hide
|
||||
| In Vitro Model | Small cell lung carcinoma | SHP-77 cells | CVCL_1693 | ||
References